|
Endometriosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Elevated expression of HSD17B7 was observed in the eutopic endometrium of EM patients.
|
27663891 |
2017 |
|
Endometriosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Involvement of 17β-hydroxysteroid dehydrogenase type gene 1 937 A>G polymorphism in infertility in Polish Caucasian women with endometriosis.
|
28405865 |
2017 |
|
Endometriosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, DNG exerts comprehensive inhibition of abnormal estrogen production through inhibition of aromatase and HSD17β1, contributing to a therapeutic effect of DNG on endometriosis.
|
25767055 |
2015 |
|
Endometriosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of type 1 17β-hydroxysteroid dehydrogenase impairs the synthesis of 17β-estradiol in endometriosis lesions.
|
24187399 |
2014 |
|
Endometriosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
17Beta-hydroxysteroid dehydrogenase-2 deficiency and progesterone resistance in endometriosis.
|
20108182 |
2010 |
|
Endometriosis
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Aromatase, 17beta-HSD types 1 and 7, sulfatase and ERbeta were statistically significantly upregulated, while ERalpha was significantly downregulated, in the endometriosis group compared with the control group.
|
17454161 |
2007 |
|
Endometriosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A stromal cell defect in endometriosis blocks formation of progesterone-dependent production of factors leading to 17beta-hydroxysteroid dehydrogenase type 2 deficiency and defective conversion of estradiol to estrone in epithelium.
|
17403431 |
2007 |
|
Endometriosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Lack of expression or a deficiency of 17beta-hydroxysteroid dehydrogenase type 2 (17beta-HSD2), a key enzyme in estradiol inactivation, could be involved in the pathophysiology of endometriosis.
|
17505937 |
2007 |
|
Endometriosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Aromatase, 17beta-HSD types 1 and 7, sulfatase and ERbeta were statistically significantly upregulated, while ERalpha was significantly downregulated, in the endometriosis group compared with the control group.
|
17454161 |
2007 |
|
Endometriosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Oestrogen metabolism, including the expression pattern of aromatase and the regulation of 17beta-hydroxysteroid dehydrogenase type 2 is altered in the eutopic endometrium of women with endometriosis, adenomyosis, and/or leiomyomas compared to that in the eutopic endometrium of women without disease.
|
16564227 |
2006 |
|
Endometriosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Another abnormality in endometriosis--deficient 17 beta-hydroxysteroid dehydrogenase (17 beta-HSD) type 2 expression--impairs the inactivation of estradiol (E2) to estrone (E1).
|
10652502 |
2001 |
|
Endometriosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Additionally, endometriotic glandular cells are deficient in 17beta-hydroxysteroid dehydrogenase type 2, which converts E2 to estrone in the eutopic endometrium in response to P. Deficiency of this enzyme in endometriosis impairs the inactivation of E2 and may be a consequence of insensitivity to P.
|
10593363 |
1999 |
|
Endometriosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrated, by Northern blotting, 17betaHSD-2 messenger ribonucleic acid (RNA) in all RNA samples of secretory eutopic endometrium (n=12) but not in secretory samples of endometriotic lesions (n=10), including paired samples of endometrium and endometriosis obtained simultaneously from eight patients.
|
9851796 |
1998 |